CN Mobile Logo

Search form


Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.

The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.

Two leading breast cancer experts debated the proposition that platinum-based or other additional systemic agents should be used in difficult-to-treat cases of high-risk triple-negative breast cancer.

In this interview we discuss the current challenges to treating triple-negative breast cancer and look at avenues of promising research.


Subscribe to Triple-Negative Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.